Fuggetta Gianluca 4

What Happened

• Gianluca Fuggetta, Gain Therapeutics' Principal Accounting and Financial Officer, was granted a derivative award covering 50,000 shares on March 24, 2026. The award was recorded at $0.00 cash consideration (i.e., no cash paid at grant) and is reported as an acquisition (award) rather than a market purchase or sale.

Key Details

• Transaction date: 2026-03-24; Filing date: 2026-03-26 (appears timely under Form 4 rules).
• Security: derivative award for 50,000 shares; reported acquisition price: $0.00.
• Vesting: 25% vests on March 24, 2027, then the remainder vests in 36 equal monthly installments thereafter, subject to continuous service (footnote F1).
• Shares owned after transaction: not specified in the provided filing details.
• No exercise or sale reported — this is a grant of a compensatory derivative (likely stock option or restricted stock unit), not an immediate cash transaction.

Context

• This is a routine compensation award to an officer and does not represent an open‑market purchase or sale. Because vesting is time‑based, the award vests over the next four years and only becomes exercisable/transferable per the schedule and company plan terms. There is no indication in this filing of any immediate sale or cashless exercise.